Skip to main content
. 2021 Dec 15;81(2):225–231. doi: 10.1136/annrheumdis-2021-221019

Table 4.

Frequently reported TEAEs

Patients, n (%) RZB 150 mg
N=483
Placebo
N=481
TEAEs reported for ≥2% of patients in either group
Nasopharyngitis 16 (3.3) 14 (2.9)
Upper respiratory tract infection 12 (2.5) 20 (4.2)
Increased ALT 13 (2.7) 10 (2.1)
Increased AST 10 (2.1) 7 (1.5)
Headache 10 (2.1) 8 (1.7)

ALT, alanine aminotransferase; AST, aspartate aminotransferase; RZB, risankizumab; TEAE, treatment-emergent adverse events.